http://forums.phoenixrising.me/attachment.php?attachmentid=2541&d=1274191474
This is a very thorough research paper about the benefits of ketamine. I'm pasting just a few things. It's kind of the everything u'd want to know about the therapeutic uses of ketamine on humans.
[Major revision to be added: weekly dosing can result in tolerance; best option for depression is prolonged subanesthetic dose infusion monthly, rather than short-course infusion weekly, so as to minimize likelihood of tolerance.]
This is the Table of Contents:
The Clinical Evidence [for ketamine] – 2
A. Refractory depression – 2
B. Refractory fibromyalgia – 4
C. Refractory chronic regional pain syndrome – 8
D. Case reports in other psychiatric and neurodegenerative disorders – 11
E. Dosing – 11
Part III. Pathogenicity in Advanced Lyme Disease – 11
A. Inflammation – 11
B. Kynurenine pathway-mediated excitotoxicity and oxidative stress – 13
Part IV. IDO/kynurenine pathway-mediated immune dysregulation – 15
A. Simplified and selective overview of some key components in adaptive immune response – 15
B. HIV- and cancer-like immunosuppression by overactivation of IDO and kynurenine pathway – 16
C. Role of IDO and kynurenine pathway in autoimmunity – 18
D. Risks of suppressing TNF-alpha and IDO – 19
Part V. Ketamine’s mechanisms of action – 20
A. Anti-inflammatory effects and neuroprotective mechanisms in excitotoxicity and oxidative stress – 20
B. Likelihood of reducing immunosuppression and possibility of terminating autoimmunity in advanced Lyme disease – 21
Part VI. Low-dose ketamine safety profile – 21
A. Side-effects – 21
B. Tolerance and addiction – 21
C. Neurotoxicity – 22
D. Effects of long-term treatment with low-dose ketamine – 22
E. Drug-drug interactions – 22
Part VII. Conclusion – 22
Figure 1. The kynurenine pathway – 24
Table 1. Inducers of IDO – 28
References – 29